Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Martín I, Villamón E, Abellán R, Calasanz MJ, Irigoyen A, Sanz G, Such E, Mora E, Gutiérrez M, Collado R, García-Serra R, Vara M, Blanco ML, Oiartzabal I, Álvarez S, Bernal T, Granada I, Xicoy B, Jerez A, Calabuig M, Diez R, Gil Á, Díez-Campelo M, Solano C, Tormo M; Spanish Group of Myelodysplastic Syndromes (GESMD). Martín I, et al. Br J Haematol. 2021 Aug;194(4):708-717. doi: 10.1111/bjh.17675. Epub 2021 Jul 22. Br J Haematol. 2021. PMID: 34296432
Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.
Santamaría C, Ramos F, Puig N, Barragán E, de Paz R, Pedro C, Insunza A, Tormo M, Del Cañizo C, Diez-Campelo M, Xicoy B, Salido E, Sánchez del Real J, Hernández M, Chillón C, Sanz GF, García-Sanz R, San Miguel JF, González M. Santamaría C, et al. Ann Hematol. 2012 Dec;91(12):1887-95. doi: 10.1007/s00277-012-1538-7. Epub 2012 Aug 9. Ann Hematol. 2012. PMID: 22875062
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
Mallo M, Del Rey M, Ibáñez M, Calasanz MJ, Arenillas L, Larráyoz MJ, Pedro C, Jerez A, Maciejewski J, Costa D, Nomdedeu M, Diez-Campelo M, Lumbreras E, González-Martínez T, Marugán I, Such E, Cervera J, Cigudosa JC, Alvarez S, Florensa L, Hernández JM, Solé F. Mallo M, et al. Br J Haematol. 2013 Jul;162(1):74-86. doi: 10.1111/bjh.12354. Epub 2013 Apr 25. Br J Haematol. 2013. PMID: 23614682 Free article.
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
Abáigar M, Ramos F, Benito R, Díez-Campelo M, Sánchez-del-Real J, Hermosín L, Rodríguez JN, Aguilar C, Recio I, Alonso JM, de las Heras N, Megido M, Fuertes M, del Cañizo MC, Hernández-Rivas JM. Abáigar M, et al. Ann Hematol. 2013 Nov;92(11):1543-52. doi: 10.1007/s00277-013-1799-9. Epub 2013 Jun 6. Ann Hematol. 2013. PMID: 23740492
Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.
Arenillas L, Mallo M, Ramos F, Guinta K, Barragán E, Lumbreras E, Larráyoz MJ, De Paz R, Tormo M, Abáigar M, Pedro C, Cervera J, Such E, José Calasanz M, Díez-Campelo M, Sanz GF, Hernández JM, Luño E, Saumell S, Maciejewski J, Florensa L, Solé F. Arenillas L, et al. Genes Chromosomes Cancer. 2013 Dec;52(12):1167-77. doi: 10.1002/gcc.22112. Epub 2013 Oct 7. Genes Chromosomes Cancer. 2013. PMID: 24123380
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Rojas SM, Díez-Campelo M, Luño E, Cabrero M, Pedro C, Calabuig M, Nomdedeu B, Cedena T, Arrizabalaga B, García M, Cerveró C, Collado R, Azaceta G, Ardanaz MT, Muñoz JA, Xicoy B, Rodríguez MJ, Bargay J, Morell MJ, Simiele A, del Cañizo C. Rojas SM, et al. Leuk Res. 2014 Mar;38(3):304-9. doi: 10.1016/j.leukres.2013.11.005. Epub 2013 Nov 15. Leuk Res. 2014. PMID: 24333115
Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.
Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, González M, Vidriales B, Sánchez-Guijo FM, López-Corral L, Luño E, del Cañizo C. Bernal T, et al. Leuk Res. 2014 May;38(5):551-6. doi: 10.1016/j.leukres.2014.02.001. Epub 2014 Feb 10. Leuk Res. 2014. PMID: 24655806
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J, Del Cañizo C, Lorenzo I, Nomdedeu B, Luño E, de Paz R, Xicoy B, Valcárcel D, Brunet S, Marco-Betes V, García-Pintos M, Osorio S, Tormo M, Bailén A, Cerveró C, Ramos F, Diez-Campelo M, Such E, Arrizabalaga B, Azaceta G, Bargay J, Arilla MJ, Falantes J, Serrano-López J, Sanz GF; Spanish Group on Myelodysplastic Syndromes (GES MD). Sánchez-García J, et al. Br J Haematol. 2014 Jul;166(2):189-201. doi: 10.1111/bjh.12876. Epub 2014 Apr 10. Br J Haematol. 2014. PMID: 24716538 Free article.
Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patients.
Díez Campelo M, Sánchez-Barba M, de Soria VG, Martino R, Sanz G, Insunza A, Bernal T, Duarte R, Amigo ML, Xicoy B, Tormo M, Iniesta F, Bailén A, Benlloch L, Córdoba I, López-Villar O, Del Cañizo MC; Spanish Registry of MDS. Díez Campelo M, et al. Leuk Res. 2014 Oct;38(10):1199-206. doi: 10.1016/j.leukres.2014.07.009. Epub 2014 Aug 1. Leuk Res. 2014. PMID: 25139847
112 results